A5000731211- Pituitary Gland Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Adrenal and Paraganglionic Tumors
- Thyroid Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Glioma Diagnosis and Treatment
- Adrenal Hormones and Disorders
- Clusterin in disease pathology
- TGF-β signaling in diseases
- Hedgehog Signaling Pathway Studies
- BRCA gene mutations in cancer
- Prostate Cancer Treatment and Research
- Liver Disease Diagnosis and Treatment
- Facial Nerve Paralysis Treatment and Research
- Cancer, Hypoxia, and Metabolism
- Bone health and osteoporosis research
- Hormonal Regulation and Hypertension
- Myasthenia Gravis and Thymoma
- PI3K/AKT/mTOR signaling in cancer
- Metabolism, Diabetes, and Cancer
- Autoimmune and Inflammatory Disorders Research
- Bioinformatics and Genomic Networks
- Diet, Metabolism, and Disease
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2020-2025
Instituto de Salud Carlos III
2023-2025
Universitat Autònoma de Barcelona
2021-2025
Centre for Biomedical Network Research on Rare Diseases
2022-2025
Hospital Universitari Germans Trias i Pujol
2021-2025
Instituto de Investigación de Enfermedades Raras
2023-2024
Hospital de Sant Pau
2023-2024
Institute of Predictive and Personalized Medicine of Cancer
2019-2021
Universitat Pompeu Fabra
2017
Pharmacologic treatment of acromegaly is currently based upon assay-error strategy, the first-generation somatostatin receptor ligands (SRL) being first-line treatment. However, about 50% patients do not respond adequately to SRL. Our objective was evaluate potential usefulness different molecular markers as predictors response We used somatotropinoma tissue obtained after surgery from a national cohort 100 acromegalic patients. Seventy-one were treated with SRL during at least 6 months...
Abstract Background Hypercortisolism in Cushing's syndrome (CS) is associated with bone loss, skeletal fragility, and altered quality. No studies evaluated geometric strain–stress values CS patients after remission thus far. Patients methods Thirty-two women (mean age [±SD] 51 ± 11; body mass index [BMI], 27 4 kg/m2; mean time of remission, 120 90 months) 32 age-, BMI-, gonadal status–matched female controls. Quantitative computed tomography (QCT) was used to assess volumetric mineral...
Abstract Context Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness about 50%, and subsequent drugs are indicated clinical judgment. Some biomarkers can predict fgSRLs response. Objective Here we report the results ACROFAST study, trial in which protocol based on predictive was evaluated. Methods This prospective (21 university hospitals) comparing...
Background: Distant metastases (DM) are the leading cause of thyroid cancer-related death in patients with differentiated cancer (DTC). Despite significant progress understanding DNA methylation DTC, landscape metastatic primary tumors and DM remains unclear. Our objective was to investigate dynamics during DTC progression, a secondary goal assessing potential clinical implications. Materials Methods: We conducted multicenter retrospective study who underwent surgery at five university...
Abstract Purpose To describe the development of AcroFace system, an AI-based system for early detection acromegaly, based on facial photographs analysis. Methods Two types features were explored: (1) visual/texture a set 2D images, and (2) geometric information obtained from reconstructed 3D model single image. We optimized acromegaly by integrating SVM CNNs visual features, each chosen their strength in processing distinct data effectively. This combination enhances overall accuracy...
Abstract Predicting which acromegaly patients could benefit from somatostatin receptor ligands (SRL) is a must for personalized medicine. Although many biomarkers linked to SRL response have been identified, there no consensus criterion on how assign this pharmacologic treatment according biomarker levels. Our aim provide better predictive tools an accurate patient stratification regarding the ability respond SRL. We took advantage of multicenter study 71 and we used advanced mathematical...
Hyperintensity signal in T2-weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment acromegaly. The aim of the study was evaluate T2 MRI intensity and its relation with effectiveness real-life clinical practice.Retrospective multicentre including acromegaly patients treated pasireotide. Adenoma at diagnosis qualitatively classified as iso-hyperintense or hypointense. Insulin-like growth factor (IGF-I), hormone (GH) tumour volume...
Acromegaly is caused by excess growth hormone (GH) produced a pituitary tumor. First-generation somatostatin receptor ligands (SRLs) are the first-line treatment. Several studies have linked E-cadherin loss and epithelial-mesenchymal transition (EMT) with resistance to SRLs. Our aim was study EMT its relationship SRLs in GH-producing tumors. We analyzed expression of EMT-related genes RT-qPCR 57 The postsurgical response categorized as complete response, partial or nonresponse if IGF-1...
// Silvia Hernández-Llodrà 1, * , Nuria Juanpere 2, de Muga 1 Marta Lorenzo 2 Joan Gil Alba Font-Tello 3 Laia Agell Raquel Albero-González Laura Segalés José Merino 4 Serrano Lluís Fumadó 5 Cecchini and Josep Lloreta Trull Department of Health Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain Pathology, Hospital del Mar-Parc Salut Mar-IMIM, Dana Farber Cancer Institute, Boston, MA, USA Fundación Jiménez Díaz, Madrid, Urology, These authors have contributed equally to this...
Different medical therapies have been developed for pituitary adenomas. However, Non-Functioning Pituitary Neuroendocrine Tumors (NF-PitNET) shown little response to them. Furthermore, epithelial-mesenchymal transition (EMT) has linked resistance treatment in a significant number of tumors, including We aimed evaluate the expression EMT-related markers 72 NF-PitNET and 16 non-tumoral pituitaries. To further explore potential usefulness we assessed somatostatin receptors dopamine-associated...
Introduction We previously described that a short version of the acute octreotide test (sAOT) can predict response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. have prospectively reassessed sAOT from ACROFAST study using current ultra-sensitive GH assays. also studied correlation tumor expression E-cadherin and 2 (SSTR2) . Methods A total 47 treated SRLs for 6 months were evaluated at diagnosis correlated SRLs’ response. Those whose IGF1 decreased...
Growth hormone (GH)-secreting pituitary tumors (GHomas) are the most common acromegaly cause. At diagnosis, of them macroadenomas, and up to 56% display cavernous sinus invasion. Biomarker assessment associated with tumor growth invasion is important optimize their management.
Abstract Objective Large somatotrophic adenomas depict poor response to somatostatin receptor ligands (SRLs). Debulking has shown enhance SRLs effect in some but not all cases and tumour volume reduction been proposed as the main predictor of response. No biological studies have performed so far this matter. We aimed identify molecular markers after surgical debulking GH‐secreting adenomas. Design a multicenter retrospective study. Patients 24 patients bearing large GH‐producing tumours....
Silent corticotroph tumors are a pituitary neuroendocrine tumor subtype of lineage that do not clinically express Cushing's disease. The silencing this type is fully understood. aim the present study was to delve into lack secretory activity, studying post-transcriptional and post-translational regulation POMC/ACTH in series molecularly identified functioning silent tumors.We analyzed 24 corticotroph, 23 25 gonadotroph used Sanger sequencing, quantitative real-time PCR Western blot analyze...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Acromegaly accounts for significant medical problems, quality of life patients impairment (QoL) and premature mortality. We describe the development AcroFace system, an AI-based system early detection acromegaly, based on facial photographs analysis.Methods: Two types features were explored: 1) visual/texture a set 2D images, 2) geometric information obtained from reconstructed 3D model single image. A regression was used building score able to estimate acromegaly 86 Caucasian non-acromegaly...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)